SCHEMBL18878998

SCHEMBL18878998

CNc1ccnc2nccnc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 2/20 0.38
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36
CDC42BPA Q5VT25 1/20 0.36
CDC42BPB Q9Y5S2 1/20 0.36
HTR1A P08908 3/20 0.35
ADRA1D P25100 3/20 0.35
ADRA1A P35348 3/20 0.35
ADRA1B P35368 3/20 0.35
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
CCR1 P32246 1/20 0.33
CCR5 P51681 1/20 0.33
CCR8 P51685 1/20 0.33
AURKA O14965 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18878943 0.72 MAPT (0.52) SLC40A1HTR1AADRA1DADRA1AADRA1B
SCHEMBL13107391 0.71 NOS3 (0.35) ALDH1A1ADORA2A
SCHEMBL2736399 0.70 MAPT (0.70) SLC40A1HTR1AADRA1DADRA1AADRA1B
SCHEMBL15268003 0.70 SLC40A1 (0.43) SLC40A1ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL3156717 0.69 CCR1 (0.54) HTR1AADRA1DADRA1AADRA1BMEN1
SCHEMBL18879077 0.68 ROCK1 (0.44) SLC40A1ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL13962401 0.67 ADORA2A (0.32) ADORA2A
SCHEMBL24896143 0.66 YTHDC1 (0.51) SLC40A1KDM4EALDH1A1ADORA2A
SCHEMBL18878954 0.66 GRM1 (0.33) SLC40A1ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL15267982 0.66 ADORA2A (0.39) SLC40A1ROCK2ROCK1CDC42BPACDC42BPB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170145009-A1 HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS EFFECTOR THERAPEUTICS, INC. 2017-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170145009-A1 HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS MAP3K9, MAP3K19, MAP3K20 SLC40A1 4174/4885ROCK2 502/4885ROCK1 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.